Furthermore, a role for CitH3 as a prognostic marker of a poor clinical outcome has been suggested [126], while determining the expression of G-CSF by tumor cells may assist in identifying individuals who are at increased risk of developing metastasis driven by NETs [114]. This evidence concerns the gene CSF3 and neoplasm.